Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022 | Read time : 02:00 min

Sandoz announces

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab.

Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.”

 Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals

Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5.

The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications.

Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901.

The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab.

Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development.

In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval.

About denosumab
Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.


The setting up of the new clinical commissioning system has given the NHS the opportunity to think about what support clinical commissioners need to more efficiently deliver better outcomes for patients. The aim is to design the most efficient and cost-effective way of providing excellent commissioning support activities, allowing CCGs to maximise their investment in frontline healthcare services for communities and improving health outcomes.


The setting up of the new clinical commissioning system has given the NHS the opportunity to think about what support clinical commissioners need to more efficiently deliver better outcomes for patients. The aim is to design the most efficient and cost-effective way of providing excellent commissioning support activities, allowing CCGs to maximise their investment in frontline healthcare services for communities and improving health outcomes.

Related News


KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

KORU Medical | October 13, 2022

KORU Medical Systems, Inc. a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions announced the appointment of Brent Rutland as the Company’s new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company’s clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company’s products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company’s efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates. “We are excited to bring Brent’s competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships. Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company’s strategy.” Linda Tharby, President and CEO Mr. Rutland’s career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology. “I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team,” said Brent Rutland, Vice President of Medical Affairs. “Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company’s overall goals.” About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System. currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.

Read More


Carbon Health Announces Best-in-Class Patient Outcomes from Diabetes Program

Carbon Health | December 01, 2022

In honor of National Diabetes Awareness Month in November, Carbon Health, a hybrid healthcare company that combines expert care with proprietary technology for easy everyday health, announces compelling new patient outcomes from its innovative diabetes program. To date, Carbon Health's diabetes program has helped two-thirds of its patients with uncontrolled diabetes achieve and maintain recommended glycemic targets, while patients with baseline A1c >9.0% in particular saw an impressive average A1c reduction of 4.2%. Carbon Health’s program is endocrinologist-led, integrated with primary care, and supported by a team of certified diabetes educators. It is also completely virtual, making it easily accessible to patients with no waiting or travel time involved. The Carbon Health electronic health record integrates data from continuous glucose monitors into the patient’s chart and enables seamless care coordination among all members of the care team. Patients are able to log meals and medications alongside their CGM data in the Carbon Health patient app, which is an everyday companion to their care. “Diabetes care traditionally involves fingerstick glucose monitoring and quarterly visits. We’re flipping that on its head with our measurement-based, personalized, and proactive diabetes program. We’re the only healthcare provider to integrate a combination of blood glucose data from a CGM device with food, physical activity, and medication into our electronic health record (EHR) to allow patients and their interdisciplinary care teams – including primary care providers – to have incredibly powerful insights at their fingertips. This continuous data better enables our care team to manage our patients virtually and offer proactive support when they need it the most, avoiding one-size-fits-all advice and broken handoffs.” Myoung Cha, Chief Strategy Officer at Carbon Health These new outcomes will be presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes and represent best-in-class results among a number of diabetes care solutions. A recent analysis of 204 patients in the program found that 66.8% with baseline A1c ≥7.0% are meeting the guideline-recommended 70% time in range in their latest four weeks of available CGM data. Meanwhile, 54.0% of this cohort reached 70% time in range in their first 4 weeks of participating in the program then maintained that target thereafter, indicating that glycemic control was achieved rapidly and effectively. Among patients with baseline A1c >9.0%, Carbon Health's diabetes program lowered A1c by an average of 4.2%, compared to 3.3% by a leading digital diabetes competitor. Additionally, Carbon Health has made the following enhancements to its diabetes program Meal rankings: This unique feature shows the connection between meals and blood sugar changes, helping patients to better understand on their own which meals they should favor or avoid/limit. Peer support: Diabetes care & education specialists facilitate peer support and open discussions through virtual group learning sessions. Educational content: Expanding the diabetes content library to increase patient knowledge includes offering an evidence-based comparison of popular diets and strategies for eating healthy on the road. Ongoing accountability: Carbon Health’s care team has developed bi-weekly notifications to support patients: celebrating when they reach their blood sugar goals and reaching out when they need help. The notifications also act as time-saving tools for providers, who can easily see changes and better drive care adherence. For those at higher risk of diabetes, including individuals with high blood pressure, high cholesterol and/or a family history of diabetes, Carbon Health also offers an improved metabolic health assessment in California. Due to the complete integration of CGM data with the Carbon Health app as well as meal rankings, the metabolic insights program now offers even more individualized and actionable insights so patients can see what works and make appropriate lifestyle shifts. Learn more and check eligibility for the metabolic insights program here. Diabetes and metabolic care at Carbon Health illustrate the company’s innovative care delivery model, Connective Care. Where typical primary care is anchored in a visit, Carbon Health combines technology and expert care so every patient can establish a relationship with their own integrated team, monitor and manage their health on the go, and access in-person care when and where they need it. “We’re proud of the outcomes that are driving real change for our patients. It’s truly only by leveraging this integrated primary care model that we are able to offer our patients care that is simple, flexible, and personal,” said Dr. Calvin Wu, Medical Director of the diabetes program and endocrinologist at Carbon Health. About Carbon Health Carbon Health is a modern healthcare company offering hybrid care for easier everyday health. By combining custom technology with expert care, Carbon Health enables patients to establish a direct relationship with an integrated team, monitor and manage their health on the go, and access in-person care when and where they need it. Building on the success of its nationwide urgent care network, Carbon Health treats the full spectrum of first-contact needs – from acute issues to chronic conditions, as well as ongoing physical and mental health needs. The company is also expanding into value-based care through work with employers, health plans, health systems, and other ecosystem partners.

Read More


WELL Health to Acquire EMR, Billing and Clinical Assets from CloudMD

WELL Health Technologies Corp. | October 12, 2022

WELL Health Technologies Corp. a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce it has entered into an agreement to acquire Cloud Practice Inc. and three clinics from CloudMD Software & Services Inc. "This transaction demonstrates our dedication to expanding and strengthening WELL's Canadian healthcare offering through disciplined capital allocation. This acquisition will also enable our EMR and billing divisions to enter new markets in the Canadian Prairies where we look forward to supporting healthcare practitioners' access to new digital health innovations." Hamed Shahbazi, CEO and Founder of WELL Cloud Practice is a medical software application company with products including Juno EMR, a cloud based EMR solution based on OSCAR1, and ClinicAid, a medical billing software used by healthcare practitioners who don't need access to a full EMR. Outside of WELL who is the largest provider of OSCAR1 EMR products and services, Juno EMR represented the largest remaining asset and market share available in the OSCAR1 based EMR industry. Both Juno EMR and ClinicAid represent WELL's entrance into the Alberta and Saskatchewan markets for its EMR and medical billing related lines of business. Both assets will be integrated into WELL's Provider Solutions Business Unit, under WELL's existing EMR and Billing platforms. Amir Javidan, COO of WELL commented, "This transaction is a win for healthcare practitioners and their patients as it will allow software users and clinicians joining our network to have access to WELL's innovative Apps.Health platform which includes dozens of apps designed by leading 3rd party digital health companies providing advanced physician tools such as an AI-powered virtual assistant to premium digital patient engagement tools that can drive significant operating efficiencies for clinics." The three primary care clinics being acquired in the Transaction currently have a total staff of 20 physicians operating out of two clinics in Vancouver, BC and one clinic in Surrey, BC. These clinics are owned by subsidiaries of CloudMD, with all of the shares of these entities being acquired as part of the Transaction. These three clinics will be integrated into WELL's existing primary care clinic network under WELL Health Canada Clinics Inc. About WELL Health Technologies Corp. WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on OTCQX under the symbol "WHTCF".

Read More